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Deregulation of the receptor tyrosine kinase RET has been implicated in medullary thyroid cancer, a
small percentage of lung adenocarcinomas, endocrine-resistant breast cancer and pancreatic cancer.
There are several clinically approved multi-kinase inhibitors that target RET as a secondary pharma-
cology but additional activities, most notably inhibition of KDR, lead to dose-limiting toxicities. There is,
therefore, a clinical need for more speciﬁc RET kinase inhibitors. Herein we report our efforts towards
identifying a potent and selective RET inhibitor using vandetanib 1 as the starting point for structure-
based drug design. Phenolic anilinoquinazolines exempliﬁed by 6 showed improved afﬁnities towards
RET but, unsurprisingly, suffered from high metabolic clearance. Efforts to mitigate the metabolic liability
of the phenol led to the discovery that a ﬂanking substituent not only improved the hepatocyte stability,
but could also impart a signiﬁcant gain in selectivity. This culminated in the identiﬁcation of 36; a potent
RET inhibitor with much improved selectivity against KDR.
© 2016 Elsevier Masson SAS. All rights reserved.1. Introduction
RET (REarranged during Transfection) is a receptor tyrosine ki-
nase (RTK) that is required for normal development, maturation
and maintenance of several tissues and cell types [1]. Gain of
function mutations in RET are implicated in several human cancers,
e.g. medullary thyroid cancer (MTC) and lung adenocarcinoma
(LAD). The identiﬁcation of these mutations and rearrangements in
RET which lead to constitutive activation, together with convincing
preclinical data validating RET as a classical oncogene, make this
kinase an attractive target for cancer therapy. At present, there are
no known speciﬁc RET inhibitors in clinical development, although.ac.uk (R. Newton).
served.many potent inhibitors of RET have been opportunistically identi-
ﬁed through selectivity proﬁling of compounds initially designed to
target other RTKs. The small molecule inhibitors vandetanib 1 and
cabozantinib 2 (Fig. 1) exemplify this approach.
Although both have been approved for the treatment of
advanced metastatic MTC [2,3] and are undergoing Phase II trials in
LAD [4,5], RET inhibition is a secondary pharmacology of these
drugs, which were initially developed as inhibitors of other re-
ceptor tyrosine kinases. Both agents target KDR (VEGFR2), whilst 1
has additional activity versus EGFR and 2 versus MET. Although it is
possible that KDR activity may contribute to their clinical efﬁcacy
[6], the results of a large Phase III trial of 1 [2] showed a signiﬁcantly
better hazard ratio for RET-positive patients compared with RET-
negative, suggesting that its efﬁcacy is strongly related to its RET
inhibitory activity. The EGFR activity of 1 is unlikely to signiﬁcantly
contribute to its efﬁcacy since it has been demonstrated that
Fig. 1. Multi-target kinase inhibitors which inhibit RET.
Fig. 2. Location of key amino acids within the ATP-binding site of RET, illustrated using
the X-ray structure of vandetanib (PDB code 2IVU). Amino acids that differ between
RET and KDR include Ser891 (KDR Cys1045), Ser811 (KDR Asn923) and Tyr806 (KDR
Phe918). Figure prepared using the Pymol Molecular Graphics System (Schr€odinger,
LLC, New York, NY).
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responses in MTC [7]. Signiﬁcant toxicity (e.g. rash, diarrhoea, hy-
pertension) resulting from inhibition of these off-target kinases,
particularly KDR, compromises the use of 1 and 2 in clinical settings
[8]. Thus, there is a clear need for selective RET inhibitors which do
not display the toxicities associated with the current treatments
and enable more potent and sustained inhibition of RET signaling.
These agentsmay offer greater clinical beneﬁt for patients with RET
mutant cancers and widen the scope for the clinical use of RET
inhibitors. Although the initial clinical line of sight for this target
was MTC, recent identiﬁcation of RET fusions (e.g. KIF5B-RET and
CCDC6-RET) present in approximately 1% of LAD patient samples
offer an important disease segment in which a speciﬁc RET inhib-
itor would also offer clinical beneﬁt. Additionally, RET has also
recently been implicated in the progression of both breast and
pancreatic tumours [9].
Our initial focus was to identify novel, low molecular weight,
ATP-competitive inhibitors of the RET kinase domain with
improved selectivity for RET against KDR in cellular assays, relative
to 1. The availability of high quality X-ray crystal structures of RET
and KDR in the public domain enabled us to pursue a structure-
guided medicinal chemistry approach to design and optimise
novel and selective inhibitors. Hit identiﬁcation employed a
focused medicinal and computational chemistry programme to
explore structure-activity relationships (SAR) around known RET
scaffolds and to determine whether selectivity could be improved
by targeting regions of the binding site that differ in sequence be-
tween RET and KDR. Although comparison of X-ray crystal struc-
tures of RET and KDR revealed that the ATP-binding pockets are
generally very similar in structure, we hypothesized that there was
potential to improve selectivity by targeting a number of speciﬁc
residues readily accessible to the ligand. The anilinoquinazoline
core of 1was selected as a scaffold expected to impart good cellular
activity and permeability, which allowed us to target binding site
residues of interest using established medicinal chemistry
methods.
The binding mode of 1 to the RET kinase domain has been re-
ported previously [10]. The quinazoline core binds to the hinge
region (Glu805-Ala807), with the anilino ring enclosed within the
hydrophobic pocket between the gatekeeper residue Val804 and
the catalytic lysine Lys758 (Fig. 2). As the gatekeeper pocket is well
known to contribute to the afﬁnity and selectivity of many series of
kinase inhibitors, we decided to focus the initial optimization of the
quinazoline series on exploring the SAR around the anilino ring,
with a view to identifying substituents that improved selectivity
towards RET. Given that the 6 and 7 positions on the quinazoline
ring point primarily towards solvent, we expected these sub-
stituents to have a less pronounced role on selectivity, and hence
ﬁxed both positions as methoxy groups for the initial round of
optimization.2. Chemistry
2.1. Synthesis of anilinoquinazolines
Quinazolines 4e45 were prepared using the commercially
available 6,7-bismethoxychloroquinazoline 3 as a simpliﬁed
analogue of 1, as illustrated in Scheme 1.2.2. Synthesis of key intermediates
Many of the required nucleophiles were commercially available;
the remainder was synthesized using known or modiﬁed chemis-
try. The routes used to prepare anilines 46aei are summarized inScheme 1. Synthesis of quinazolines.
Scheme 3. Synthesis of anilinophenols via nitro reduction. aReagents and conditions:
(a) Pd/C, H2, EtOH or (b) Fe, AcOH, EtOH.
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were the requisite methyl ethers 47a-d or nitro compounds 48aec,
which could be demethylated or reduced using standard pro-
cedures as shown in Schemes 2 and 3.
Alternative precursors to the anilinophenols were the corre-
sponding bromides. These could be converted to the boronate es-
ters 49hei, then oxidized to the required phenols 46hei as shown
in Scheme 4.
Attempts to prepare 3-amino-2-(triﬂuoromethyl)phenol were
unsuccessful. Instead, benzyl ether 50 was prepared from com-
mercial starting material then converted to aniline 51. This was
coupled directly with 3, then deprotected to return the desired
quinazoline 17 as shown in Scheme 5.
N-Methylated phenol 53 was prepared by reduction of the
corresponding N-Boc material 52 (Scheme 6).3. Results and discussion
3.1. Biochemical evaluation
Our initial aim was to prepare to number of anilinoquinazo-
lines to explore the afﬁnity and selectivity towards RET as
compared to 1 [11,12]. The biochemical data for selected com-
pounds are shown in Table 1. First, we ascertained that switching
from the more decorated quinazoline core present in 1 to the bis-
methoxy scaffold present in 4 showed only a 2-fold drop in af-
ﬁnity (data for 1 not shown). Therefore, we opted to use this
simpliﬁed scaffold for further exploration, given it was commer-
cially available. Of the ﬁrst swathe of approximately 30 simple
anilinoquinazolines prepared, the most interesting observation
was that phenol 6 resulted in a signiﬁcant gain in afﬁnity towards
RET. The same level of afﬁnity was not maintained in the isomeric
compounds 5 and 7, or for the analogous aniline 8 or the corre-
sponding methoxy ether 9.3.2. Structural considerations
The boost in RET afﬁnity from the R2 hydroxyl group may be
rationalised by consideration of the hydrogen bonding contacts
formed in the gatekeeper pocket. Initial modelling of 6, subse-
quently conﬁrmed by the determination of the X-ray structure
bound to RET (Fig. 3), highlighted a pair of hydrogen bonds from the
phenol to the side-chain of Glu775 (the conserved glutamate
located on the aC-helix) and the backbone NH of Asp892 (from the
conserved DFG motif). It is likely that this speciﬁc network of
hydrogen bonds is responsible for the gain in afﬁnity and the tight
SAR for the R2 hydroxyl, with alternative polar R2 substituents or
hydroxyls in the R1 or R3 positions all demonstrating reduced
afﬁnity
Comparison of the X-ray structures of 6 and 1 reveals that the
ligands share very similar binding modes. The anilino ring of 6
binds between the gatekeeper Val804 and the catalytic lysine
Lys758 and, in comparison to 1, shows a small rotation towardsScheme 2. Synthesis of anilinophenols via demethylation. aReagents and conditions:
(a) BBr3, DCM, -78 C or (b) pyridinium chloride, 150 C.Asp892, with minor re-orientation of neighbouring side-chains
consistent with the formation of hydrogen-bonding interactions
between the phenol and Glu775/Asp892. The most substantial
structural change is the displacement of the phosphate-binding
loop away from the ATP binding site in the X-ray structure of 6;
this may be a consequence of a degree of induced ﬁt in the ligand
binding site or may simply reﬂect the inherent ﬂexibility of this
loop. Comparisonwith X-ray structures of 6 bound to other kinases,
e.g. to CDK2, CDPK1 and TTBK1 (PDB codes 1DI8, 3NYV and 4BTK,
respectively), reveal a variety of different conformations and
hydrogen bonding interactions for the phenol moiety, distinct from
that observed for 6 bound to RET. Thus it should be possible to
modulate the selectivity of this series by appropriate substitution
around the anilino ring.
3.3. Mitigation of DMPK concerns and delivery of unanticipated
selectivity
The presence of a phenol was some cause for concern given it
was anticipated to undergo phase II metabolism. Measurement of
in vitro DMPK properties (data not shown) of the initial compound
6 showed that solubility and CYP inhibition were acceptable at this
stage, although the permeability and efﬂux needed improvement.
Observation of metabolism in microsomes, albeit to a 3-fold lesser
extent than in hepatocytes, indicated phase I metabolism was
occurring in addition to phase II.
In order to mitigate phase II metabolism, we explored further
substitution on the phenolic aniline. Our goals here were two-fold.
First, it was speculated that the presence of ﬂanking substituents
might attenuate the propensity of the phenol to undergo conju-
gation, thereby increasing hepatocyte stability. Second, it would
allow a more general SAR exploration to determine what func-
tionality could be tolerated around the phenyl ring.
We ﬁrst prepared a number of mono-substituted anilinophe-
nols. Most of these bore a ﬂanking substituent either at the R1 or R3
position, primarily to investigate whether the hepatocyte stability
could be mitigated through steric encumbrance. However, it soon
became apparent that a suitable R1 substituent also had a consid-
erable inﬂuence on KDR selectivity (10e13); albeit with some loss
of RET afﬁnity for 11e13. This selectivity enhancement was less
evident with ﬂuorine (14), whereas larger substituents were not
tolerated, as indicated by the large drop in RET afﬁnity (15e18).
Conversely, a ﬂanking substituent at R3 (19e22) was tolerated with
respect to RET afﬁnity but selectivity was comparable to, or worse
than, the unsubstituted phenol 6. Although we anticipated that any
improvement in hepatocyte stability would be most likely achieved
by exploiting substitution at the ﬂanking R1 or R3 positions, limited
examples of substitution at the R4 or R5 positionwere also explored.
Halogens were tolerated at R4 and R5 (23, 25e26) but a methyl
group resulted in a modest drop in afﬁnity, especially at the R4
position (24 and 27).
In addition to these mono-substituted examples, we also pre-
pared a number of di-substituted anilinophenols. Appropriately
positioned halogens generally retained or enhanced afﬁnity but
Scheme 4. Synthesis of anilinophenols via boronate oxidation. aReagents and condi-
tions: (a) Pd(dppf)Cl2$DCM, bis(pinacolato)diboron, 1,4-dioxane; (b) sodium perborate,
THF, water.
Scheme 6. Synthesis of 53. aReagents and conditions: (a) LiAlH4, THF.
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either H or F at the R1 position (28e34).
Clearly, incorporation of a suitable group at the R1 position was
beneﬁcial for selectivity, although afﬁnity was somewhat dimin-
ished, especially when R1 was Me. Given that halogens, especially
ﬂuorine, at R5 had been seen to generally enhance afﬁnity, it was
encouraging to see that combining these two observations resulted
in compounds which now exhibited both improved afﬁnity and
selectivity (35e37). When R1 was ﬁxed as chloro, substituting at R3
with a methyl group was detrimental with regard to selectivity
(compare 12with 38). Further substitution at R5 with chlorine (39)
was tolerated whereas ﬂuorine (40) appeared to be beneﬁcial, both
in terms of afﬁnity and selectivity.
Modelling of this series in RET suggests that the R1 methyl
substituent is positioned close to the side-chain of Ser891 (imme-
diately preceding the DFG motif), and this potentially disfavoured
contact could account for the observed reduction in RET afﬁnity
compared with 6 (Fig. 4). In KDR, Ser891 is replaced by a bulkier
cysteine (Cys1045). Hence, although the R1 methyl is somewhat
disfavoured in RET, there is a larger drop-off in afﬁnity against KDR,
leading to an improved selectivity proﬁle towards RET overall.3.4. Evaluation in cellular assays
A number of these compounds (selected on the basis of afﬁnity
and/or selectivity) were progressed into BaF3 cellular assays for RET
and KDR, the results of which are shown in Table 2. Disappointingly,
the afﬁnity and selectivity observed for this phenolic series in the
biochemical assay did not transfer well to the cellular context. Only
4 compounds (25, 26, 28 and 30) were <100 nM against RET in the
cellular assay and only one compound (40) showed >10-fold
selectivity versus KDR. In contrast, 17 compounds were 10 nM
in the biochemical assay and 22 compounds showed >10-fold
selectivity. For reasons not fully understood, the disconnect from
the biochemical to cellular assay is much greater for RET than KDR,
in effect compressing the selectivity margins, often from >100-fold
in the biochemical assay to parity (or worse) in the cellular assay.
Permeability was not believed to be the cause for the disparity as
the observed reduction in afﬁnity was not of the same magnitudeScheme 5. Synthesis of a benzyl-protected anilinophenol. aReagents and conditions: (a) BnO
HCl, THF; (c) 3, IPA; (d) TFA.for both RET and KDR in a matched cell line. The afﬁnity for ATP in
the biochemical assay is also unlikely to explain the difference in
the reduction as the Km values for both proteins (RET 9 mM and KDR
8 mM) were similar. Interestingly, the non-phenolic quinazoline 4
does not appear to suffer to the same extent.
The discrepancy between biochemical and cellular selectivity
may be related to the bindingmode of the R2 phenol. Modelling of 6
in various published X-ray structures of KDR suggested that the
hydrogen bonding network around the phenol in RET may be less
readily achievable in KDR. This is a consequence of KDR X-ray
structures displaying a conformation in which the aC-helix is dis-
placed away from the ATP binding site in comparison to RET. The
associatedmovement of the conserved glutamate located on the aC-
helix (equivalent to Glu775 in RET) would likely compromise the
formation of the pair of hydrogen bonds to the phenol observed
crystallographically in RET. This “aC-helix-out” motif is typically
characteristic of an inactive kinase conformation. It may be that the
differencebetweenbiochemical andcell selectivityproﬁles is related
to different populations of active/inactive RET conformations under
the different assay conditions. Thus, under the conditions of the
biochemical assay, RET may exist predominantly in the active
conformation characterized in the available X-ray structures,
whereas in the cellular context there may be a larger population of
inactive conformations, similar to the “aC-helix-out” conformation
observed in KDR X-ray structures, to which binding of the phenol is
less favoured. Regardless of the explanation for the observed dif-
ferences, the decision was taken that the more physiologically rele-
vant cellular datawoulddrive subsequent progression of the project.3.5. Investigation of alternate chemotypes
Different linkers were investigated as an alternative to the ani-
line but showed no improvement in comparison to 6. As shown in
Table 3, it can be seen that theN-methyl analogue 41 is signiﬁcantly
less potent than the NH-, O- and S-linked analogues (6, 42 and 43).
Although 42 and 43 retain biochemical afﬁnity as compared to 6,
they too suffer from a disproportionate reduction in afﬁnity against
RET compared to KDR in the cell assay.
Despite the drop in afﬁnity of the N-methylated analogue 41, it
retained some activity. Based upon this observation, the tethered
compounds 44 and 45were synthesized to test the hypothesis that
these may deliver the same gain in selectivity as did the 2-H, NaH, DMF; (b) (i) benzophenoneimine, Pd(OAc)2, BINAP, Cs2CO3, 1,4-dioxane; (ii) 2 M
Table 1
Biochemical data of selected anilinoquinazolines.a
Cpd Ar RET IC50 (nM) KDR IC50 (nM) Selectivity
R1 R2 R3 R4 R5
1 n/a 49 (29) 175 (86) 3
2 n/a 650 (580) 16 (31) <1
4 F H Br H H 100 (16) 460 (44) 5
5 OH H H H H 1600 (220) >10000 6
6 H OH H H H 4.5 (4.4) 66 (30) 15
7 H H OH H H 720 (48) 2800 (510) 4
8 H NH2 H H H 590 (260) 7600 (2700) 13
9 H OMe H H H 1200 (330) 4800 (410) 4
10 OH OH H H H 3.9 (2) 2300 (1100) 590
11 Br OH H H H 23 (8.3) 4100 (2200) 178
12 Cl OH H H H 19 (5.9) 2500 (1600) 132
13 Me OH H H H 190 (76) >10000 50
14 F OH H H H 10 (2.6) 280 (120) 28
15 OMe OH H H H 1100 (290) >10000 9
16 Et OH H H H 3800 (18) >10000 3
17 CF3 OH H H H 5500 (2000) >10000 2
18 CN OH H H H >10000 >10000 nd
19 H OH F H H 3.2 (1.2) 72 (36) 23
20 H OH Me H H 4.6 (0.28) 18 (9.5) 4
21 H OH Cl H H 10 (8.6) 58 (14) 6
22 H OH OMe H H 11 (2.1) 73 (54) 7
23 H OH H F H 2.6 (1.1) 66 (71) 25
24 H OH H Me H 29 (22) 350 (300) 12
25 H OH H H F 1.1 (0.54) 20 (8.8) 18
26 H OH H H Cl 2.6 (0.78) 71 (45) 27
27 H OH H H Me 8.4 (1.9) 160 (53) 19
28 H OH F H F 0.41 (0.15) 9.5 (6.5) 23
29 H OH Cl H Cl 5 (2.8) 15 (4.3) 3
30 H OH Me H F 0.75 (0.071) 2.3 (0.071) 3
31 H OH Me H Cl 13 (4.4) 17 (8.8) 1
32 F OH F H H 2 (0.39) 230 (150) 115
33 F OH H H F 1.7 (0.33) 69 (14) 41
34 F OH H H Cl 4.8 (1.4) 230 (77) 48
35 Me OH H F H 21 (8.6) 5900 (1500) 281
36 Me OH H H F 44 (5.7) 5700 (1400) 130
37 Me OH H H Cl 120 (28) >10000 83
38 Cl OH Me H H 9.3 (5.2) 360 (260) 39
39 Cl OH H H Cl 9.7 (13) 1400 (860) 144
40 Cl OH H H F 3.9 (0.5) 1100 (160) 282
a Biological values are expressed as the geometric mean of four independent
determinations and standard deviations are quoted in parentheses.
R. Newton et al. / European Journal of Medicinal Chemistry 112 (2016) 20e3224substituted analogues described earlier. However, although this
was observed biochemically for 44, these biochemical activities
again did not translate to cellular potency and selectivity, as shown
in Table 4.3.6. Further biological proﬁling
As mentioned previously, the initial interest in preparing
phenolic anilines with ﬂanking substituents was to mitigate the
anticipated metabolic liability of the phenol. Table 5 shows the
human hepatocyte stability data for selected compounds, ranked
from most to least stable. Although compounds 10, 11 and 12
beneﬁtted from an improved selectivity proﬁle compared to
unsubstituted 6, the R1 groups in these examples were detrimental
to hepatocyte stability. Pleasingly, 13 did show the desiredimprovement in stability, albeit with a 20-fold reduction in afﬁnity.
Inclusion of ﬂuorine at either the R4 or R5 positions went someway
toward recovering the afﬁnity but it can be seen that 36 is preferred
over 35 with regard to hepatocyte stability. Interestingly, the iso-
mer 30, bearing the ﬂanking substituent in the R3 position rather
than the R1 position as in 36, is signiﬁcantly less stable. Unfortu-
nately, 33, 34 and 40 (the most promising compounds with regard
to afﬁnity and selectivity in the cell assay) all suffered from high
clearance.
There does not appear to be a clear correlation between stability
and phenol pKa, indicating other effects (e.g. steric inﬂuence of the
ﬂanking substituent or contributions from other substituents in the
case of the di-substituted examples) are contributing to the
observed clearance across the series. Looking at those compounds
mono-substituted at R1 (13, 10, 11 and 12), only the Me-substituted
compound 13 shows an improvement in clearance when compared
to the unsubstituted phenol 6. Although it is true that, for this
particular set of compounds, a lower pKa results in higher clearance,
this is not observed in all cases. Isomeric pair 30 and 36 have
identical calculated pKa values yet differ only by the position of the
ﬂanking Me substituent, indicating that substitution with a Me
group at the R3 position is detrimental to metabolic stability.
Comparison of 30, 35 and 36 shows the inclusion of F at R5 is
beneﬁcial, although the effect on pKa is negligible, whereas inclu-
sion of Fat R4 resulted in a considerably lower phenol pKa andhigher
clearance. Compounds containing a halogen at both R1 and R5 dis-
played lower clearances than those only substituted with a halogen
at R1, despite similar pKa values (compare 33, 34, 40, 11 and 12),
again indicating that blocking R5 is beneﬁcial. There does not appear
to be any correlation between clearance and predicted logP (XLogP).
These compounds were also tested for non-speciﬁc cellular
toxicity, and, with the possible exception of 30, all were found to be
devoid of non-speciﬁc toxicity in a wild-type BaF3 cell line, the
parental cell line used to prepare the RET and KDR driven cell lines
used in our routine screening assays. This pleasing result further
suggests that the compounds display meaningful kinase selectivity
in the cellular context and do not promiscuously inhibit off-target
kinases responsible for cell proliferation and survival.
On the basis of these data, 36 was selected for further in vitro
and in vivo pharmacokinetic assessment. In terms of metabolic
stability, intrinsic clearance was higher in human hepatocytes than
in human microsomes (CLint 6.2 mL/min/mg), indicative of phase II
metabolism. Metabolism was more rapid in mouse in both micro-
somes and hepatocytes (CLint 28.2 mL/min/mg and 38.1 mL/min/
106 cells, respectively). In terms of physical properties, 36 showed
good aqueous solubility (in excess of 100 mM) but only moderate
permeability in Caco-2 cells (Papp 8.2  106 cm s1, efﬂux ratio
4.9). Pharmacokinetics were measured in the mouse via intrave-
nous and oral routes of administration. Total blood clearance was
low (<10% LBF) and bioavailability was approximately 35%. Oral
half-life was measured at approximately 2 h.
4. Conclusion
A structure-based drug design programme led to a series of
phenolic anilinoquinazolines showing high afﬁnity for RET in the
biochemical context. Concern over the metabolic liability of phenol
6 prompted exploration of ﬂanking substituents to attenuate the
propensity of the phenol to undergo phase II metabolism. Pleas-
ingly, incorporation of Me at R1 not only resulted in improved
metabolic stability but also in an unexpected gain in selectivity over
KDR, which could be rationalised by modelling. The improved
selectivity was accompanied by some reduction in afﬁnity but this
could be recovered to some extent by inclusion of ﬂuorine at the R5
position, resulting in 36; a potent and selective RET inhibitor.
Fig. 3. Detail of phenol interactions in the gatekeeper pocket of RET X-ray structures. (A) Crystal structure of compound 6 bound to RET kinase domain, highlighting hydrogen-
bonding interactions to Glu775 and Asp892NeH (PDB 5AMN). (B) Comparison of compound 6 with the published structure of 1 (PDB 2IVU, carbon atoms in purple). Hydrogen
atoms modelled using Maestro and ﬁgure prepared using the Pymol Molecular Graphics System (Schr€odinger, LLC, New York, NY). (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
R. Newton et al. / European Journal of Medicinal Chemistry 112 (2016) 20e32 25However, for reasons not fully understood, the translation of
biochemical potency to cellular potency was disproportionate
when comparing RET and KDR, in effect compressing the apparent
selectivity observed in the biochemical assay. Further efforts to
improve both the cellular afﬁnity and selectivity and the ADME
properties of 36 are underway in our laboratory.
5. Experimental
5.1. Chemistry
All reagents obtained from commercial sources were used
without further puriﬁcation. Anhydrous solvents were obtainedFig. 4. Compound 36 modelled in RET (green carbon atoms), compared with the
aligned X-ray structure of KDR (PDB 3CJG, orange carbons). The R1 methyl group ap-
proaches close to the sidechain of Ser891 of RET, equivalent to the bulkier Cys1045 of
KDR. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)from the Sigma-Aldrich Chemical Co. Ltd. or Fisher Chemicals Ltd.
and used without further drying. Solutions containing products
were either passed through a hydrophobic frit or dried over
anhydrous MgSO4 or Na2SO4, and ﬁltered prior to evaporation of
the solvent under reduced pressure. Thin layer chromatography
(TLC) was conducted with 5 cm  10 cm plates coated with Merck
type 60 F254 silica gel to a thickness of 0.25 mm. Chromatography
was performed on Biotage SNAP HP-Sil cartridges using a Combi-
Flash Companionmachine. Proton (1H) NMR spectra were recorded
on a 300 MHz Bruker spectrometer at ambient temperature. So-
lutions were typically prepared in either deuterochloroform
(CDCl3) or deuterated dimethylsulfoxide (DMSO-d6) with chemical
shifts referenced to deuterated solvent as an internal standard. 1H
NMR data are reported indicating the chemical shift (d), the mul-
tiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br,
broad; dd, doublet of doublets, etc.), the coupling constant (J) in Hz
and the integration (e.g. 1H). Deuterated solvents were obtained
from the Sigma-Aldrich Chemical Co., Goss or Fluorochem. LCMS
spectrawith UV detectionwere recorded on aWaters Acquity UPLC.
Mass spectrometry was performed on a Waters Acquity SQD
quadrupole spectrometer running in dual ESþ and ESmode. High
pH runs were conducted at pH 10 and low pH runs were conducted
at pH 4, with a run time of 2 min. The column temperature was
40 C, and the ﬂow rate was 0.6 mL/min. Further details, including
solvent gradients, are given in the Supporting Information. Details
of the preparative HPLC instrument and the solvent gradient used
to purify compounds are also given in the Supporting Information.
All compounds were 95% purity as determined by examination of
both the LCeMS and 1H NMR spectra unless otherwise indicated.
When Cl or Br was present, expected isotopic distribution patterns
were observed.5.1.1. General procedure for synthesis of quinazolines
4-Chloro-6,7-dimethoxyquinazoline 3 and the required nucle-
ophile were heated in solvent either thermally or using microwave
heating until no further reaction was observed. On cooling, the
hydrochloride salt was isolated by ﬁltration. Alternative isolation
procedures were employed if precipitation did not occur. Addi-
tional puriﬁcation by preparative HPLC or ﬂash column
Table 2
Cellular data for selected anilinoquinazolines.a
Cpd Ar RET IC50 (nM) KDR IC50 (nM) Cell selectivity ratio Biochemical selectivity ratio
R1 R2 R3 R4 R5
1 n/a 400 (160) 630 (190) 1 3
2 n/a 190 (160) 14 (3) <1 <1
4 F H Br H H 1700 (290) 2900 (410) 2 5
6 H OH H H H 380 (150) 890 (27) 2 15
10 OH OH H H H 1100 (160) 5700 (710) 5 590
11 Br OH H H H 2400 (380) >10000 4 178
12 Cl OH H H H 1900 (430) >10000 5 132
13 Me OH H H H 6300 (870) >10000 2 50
14 F OH H H H 570 (87) 1300 (220) 2 28
19 H OH F H H 490 (140) 360 (88) <1 23
20 H OH Me H H 500 (77) 88 (7.4) <1 4
21 H OH Cl H H 940 (420) 110 (15) <1 6
22 H OH OMe H H 1900 (57) 310 (64) <1 7
23 H OH H F H 200 (65) 260 (49) 1 25
24 H OH H Me H 1500 (280) 1200 (240) <1 12
25 H OH H H F 53 (9) 98 (14) 2 18
26 H OH H H Cl 85 (29) 240 (64) 3 27
27 H OH H H Me 460 (100) 1400 (100) 3 19
28 H OH F H F 53 (12) 66 (8.1) 1 23
29 H OH Cl H Cl 1400 (430) 280 (79) <1 3
30 H OH Me H F 41 (13) 9.5 (5.8) <1 3
32 F OH F H H 2000 (170) 4700 (1100) 2 115
33 F OH H H F 120 (21) 770 (95) 6 41
34 F OH H H Cl 270 (24) 1900 (160) 7 48
35 Me OH H F H 2100 (1210) >10000 5 281
36 Me OH H H F 2100 (260) >10000 5 130
37 Me OH H H Cl 3600 (1100) >10000 3 83
38 Cl OH Me H H 460 (170) 1000 (210) 2 39
39 Cl OH H H Cl 2200 (190) >10000 5 144
40 Cl OH H H F 260 (25) 5400 (1100) 21 282
a Most of these data are expressed as the geometric mean of at least four independent determinations and standard deviations are quoted in parentheses.
Table 3
Biochemical and cellular data for alternative linkers.
Cpd X Biochemical dataa Cellular datab
RET IC50 (nM) KDR IC50 (nM) Selectivity RET IC50 (nM) KDR IC50 (nM) Selectivity
41 NMe 210 (58) 4200 (990) 20 7200 (560) >10000 1
42 O 16 (0.28) 150 (62) 9 620 (95) 840 (130) 1
43 S 23 (0.42) 210 (10) 9 2000 (190) 1500 (83) <1
a Biological values are expressed as the geometric mean of four independent determinations and standard deviations are quoted in parentheses.
b Most of these data are expressed as the geometric mean of at least four independent determinations and standard deviations are quoted in parentheses.
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for compounds 4 [13], 6e9 [14e16], 20e21 [13], 25 [13], 28 [17] and
30 [18] are in agreement with those reported in the literature.5.1.1.1. 2-((6,7-Dimethoxyquinazolin-4-yl)amino)phenol hydrochlo-
ride (5). A mixture of 3 (100 mg, 0.45 mmol) and 2-aminophenol
(49 mg, 0.45 mmol) in MeCN afforded 5 (90 mg, 55%) as a yellow
solid. 1H NMR (300MHz, DMSO-d6) d 11.09 (br s, 1H), 9.90 (br s, 1H),
Table 4
Biochemical and cellular data for tethered compounds.
Cpd n Biochemical dataa Cellular datab
RET IC50 (nM) KDR IC50 (nM) Selectivity RET IC50 (nM) KDR IC50 (nM) Selectivity
44 1 60 (12) 9500 (1100) 158 4940 (1020) >10000 2
45 2 4100 (110) >10000 2 nd nd nd
a Biological values are expressed as the geometric mean of four independent determinations and standard deviations are quoted in parentheses.
b Most of these data are expressed as the geometric mean of at least four independent determinations and standard deviations are quoted in parentheses.
Table 5
Further proﬁling of selected quinazolines.
Cpd Ar CLint (mL/min/106 cells) Predicted pKaa XLogPb Cytotoxicity IC50 (nM)c
R1 R2 R3 R4 R5
6 H OH H H H 76.9 9.6 2.78 >10000
10 OH OH H H H 95.5 9.3 2.41 >10000
11 Br OH H H H 157 8.0 3.58 >10000
12 Cl OH H H H 174 8.1 3.40 >10000
13 Me OH H H H 28.4 9.9 3.06 >10000
30 H OH Me H F 91.9 10.0 3.16 >1000
33 F OH H H F 68.9 8.3 2.98 >10000
34 F OH H H Cl 93.3 7.9 3.50 >10000
35 Me OH H F H 54.8 8.9 3.16 >10000
36 Me OH H H F 20.9 10.0 3.16 >10000
40 Cl OH H H F 66.7 8.1 3.50 >10000
a Calculated using ACD/Percepta, 2012 release (build 2254), Advanced Chemistry Development, Inc., Toronto, ON, Canada, www.acdlabs.com.
b Calculated using Dotmatics software suite, Dotmatics, Bishops Stortford, Herts, UK, www.dotmatics.com.
c Cell cytotoxicity was measured in a matched wild-type (non RET-driven) BaF3 cell line.
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7.20e7.28 (m, 1H), 7.04 (dd, J ¼ 1.18, 8.15 Hz, 1H), 6.91 (dt, J ¼ 1.27,
7.56 Hz, 1H), 4.00 (s, 3H), 3.99 (s, 3H).
5.1.1.2. 3-((6,7-Dimethoxyquinazolin-4-yl)amino)benzene-1,2-diol
hydrochloride (10). A mixture of 3 (898 mg, 4.0 mmol) and 3-
amino-1,2-benzenediol (500 mg, 4.0 mmol) in MeCN afforded 10
(1.24 g, 89%) as a dark brown solid. 1H NMR (300 MHz, DMSO-d6)
d 10.96 (br s,1H), 9.54 (s,1H), 8.99 (br s,1H), 8.71 (s,1H), 8.16 (s,1H),
7.31 (s, 1H), 6.84 (dd, J ¼ 2.17, 7.16 Hz, 1H), 6.69e6.81 (m, 2H), 4.00
(s, 3H), 3.98 (s, 3H). 13C NMR (75 MHz, DMSO-d6): d 158.9, 156.0,
149.9, 148.5, 146.5, 141.0, 135.4, 124.4, 118.5, 118.2, 114.6, 106.9,
103.9, 99.9, 563, 56.3. HRMS (ESI) m/z [M þ H]þ calcd for
C16H15N3O4: 314.1140. Found: 314.1141.
5.1.1.3. 2-Bromo-3-((6,7-dimethoxyquinazolin-4-yl)amino)phenol
hydrochloride (11). A mixture of 3 (200 mg, 0.89 mmol), 3-amino-
2-bromo-phenol [19] (167 mg, 0.89 mmol) and 5e6N HCl in IPA
(0.01 mL) in IPA afforded 11 (310 mg, 92%) as a cream solid. 1H NMR(300 MHz, DMSO-d6) d 11.30 (br s, 1H), 10.62 (s, 1H), 8.75 (s, 1H),
8.14 (s, 1H), 7.29e7.35 (m, 2H), 7.04 (dd, J ¼ 1.41, 8.19 Hz, 1H), 6.97
(dd, J ¼ 1.41, 7.82 Hz, 1H), 4.01 (s, 3H), 3.99 (s, 3H). 13C
NMR (75 MHz, DMSO-d6): d 159.1, 156.4, 155.5, 150.2, 148.6, 136.8,
135.3, 128.3, 119.6, 115.4, 110.0, 106.6, 103.6, 99.7, 56.7, 56.5. HRMS
(ESI) m/z [M þ H]þ calcd for C16H14BrN3O3: 376.0297. Found:
376.0297.5.1.1.4. 2-Chloro-3-((6,7-dimethoxyquinazolin-4-yl)amino)phenol
hydrochloride (12). A mixture of 3 (1.56 g, 6.97 mmol) and 3-
amino-2-chlorophenol (1.0 g, 6.97 mmol) in MeCN afforded 12
(2.21 g, 86%) as a beige solid. 1H NMR (300 MHz, DMSO-d6) d 11.45
(br s, 1H), 10.59 (s, 1H), 8.77 (s, 1H), 8.22 (s, 1H), 7.36 (s, 1H), 7.27 (t,
J ¼ 7.72 Hz, 1H), 7.08 (dd, J ¼ 1.22, 8.29 Hz, 1H), 6.98 (dd, J ¼ 1.13,
7.82 Hz, 1H), 4.01 (s, 3H), 4.00 (s, 3H). 13C NMR (75 MHz, DMSO-d6):
d 157.5, 154.1, 153.1, 148.7, 146.7, 137.4, 126.8, 119.5, 118.2, 113.9,
108.5, 107.0, 101.9, 56.0, 55.7. HRMS (ESI) m/z [M þ H]þ calcd for
C16H14ClN3O3: 332.0802. Found: 332.0805.
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hydrochloride (13). A mixture of 3 (500 mg, 2.23 mmol) and 3-
amino-2-methylphenol (274 mg, 2.23 mmol) in IPA afforded 13
(708 mg, 91%) as a purple solid. 1H NMR (300 MHz, DMSO-d6)
d 11.37 (s, 1H), 9.73 (s, 1H), 8.70 (s, 1H), 8.27 (s, 1H), 7.36 (s, 1H), 7.11
(t, J¼ 7.96 Hz, 1H), 6.90 (d, J¼ 8.01 Hz, 1H), 6.77 (d, J ¼ 7.72 Hz, 1H),
3.99 (s, 6H),1.98 (s, 3H). 13C NMR (75MHz, DMSO-d6): d 158.9,156.2
( 2), 150.1, 148.7, 136.2,134.9, 126.2, 121.7, 117.9, 114.0, 106.5, 103.9,
99.5, 56.7, 56.4. HRMS (ESI) m/z [M þ H]þ calcd for C17H17N3O3:
312.1348. Found: 312.1362.
5.1.1.6. 3-((6,7-Dimethoxyquinazolin-4-yl)amino)-2-ﬂuorophenol
(14). A mixture of 3 (75 mg, 0.33 mmol) and 3-amino-2-
ﬂuorophenol (42 mg, 0.33 mmol) in MeCN returned the crude
product which was puriﬁed by preparative HPLC (high pH) to afford
14 (21 mg, 18%) as a white solid. 1H NMR (300 MHz, DMSO-d6)
d 9.90 (s, 1H), 9.54 (br s, 1H), 8.36 (s, 1H), 7.83 (s, 1H), 7.18 (s, 1H),
6.97e7.05 (m, 1H), 6.84e6.93 (m, 2H), 3.94 (s, 6H).
5.1.1.7. 3-((6,7-Dimethoxyquinazolin-4-yl)amino)-2-methoxyphenol
(15). A suspension of 3 (20 mg, 0.09 mmol), 46h (14 mg,
0.10 mmol) and 5e6N HCl in IPA (0.02 mL) in IPA was heated at
100 C for 30 min in the microwave. The reaction was concentrated
to dryness then partitioned between EtOAc and NaHCO3. A pre-
cipitate formed which was collected by ﬁltration, washed with
water (5 mL) and ether (5 mL) and dried under vacuum to give 15
(7 mg, 23%) as a white solid. 1H NMR (300 MHz, DMSO-d6) d 9.38 (s,
1H), 9.18 (s, 1H), 8.32 (s, 1H), 7.81 (s, 1H), 7.16 (s, 1H), 6.90e6.99 (m,
2H), 6.77 (dd, J¼ 2.26, 7.44 Hz, 1H), 3.93 (s, 3H), 3.93 (s, 3H), 3.65 (s,
3H).
5.1.1.8. 3-((6,7-Dimethoxyquinazolin-4-yl)amino)-2-ethylphenol
(16). A mixture of 3 (115 mg, 0.51 mmol), 46a (70 mg, 0.51 mmol)
and 5e6N HCl in IPA (0.03 mL) in IPA returned the crude product
which was puriﬁed by preparative HPLC to afford 16 (1.6 mg, 1%) as
an off white solid. 1H NMR (300 MHz, DMSO-d6) d 9.41 (br s, 1H),
9.27 (s, 1H), 8.23 (s, 1H), 7.83 (s, 1H), 7.14 (s, 1H), 7.04 (t, J ¼ 7.97 Hz,
1H), 6.78 (d, J ¼ 7.77 Hz, 1H), 6.70 (d, J ¼ 7.68 Hz, 1H), 3.92 (s, 3H),
3.91 (s, 3H), 0.97 (t, J ¼ 7.44 Hz, 3H) e CH2 of Et obscured under
DMSO solvent peak.
5.1.1.9. 3-((6,7-Dimethoxyquinazolin-4-yl)amino)-2-(tri-
ﬂuoromethyl)phenol (17). A mixture of 3 (52 mg, 0.23 mmol), 51
(61 mg, 0.23 mmol) and 5e6N HCl in IPA (0.03 mL) in IPA returned
the crude product which was puriﬁed by preparative HPLC to afford
N-[3-benzyloxy-2-(triﬂuoromethyl)phenyl]-6,7-dimethoxy-quina-
zolin-4-amine (32 mg, 31%) as a white solid. 1H NMR (300 MHz,
DMSO-d6) d 9.57 (s, 1H), 8.27 (s, 1H), 7.79 (s, 1H), 7.63 (t, J¼ 8.44 Hz,
1H), 7.29e7.51 (m, 6H), 7.17 (s, 1H), 7.04 (d, J ¼ 8.19 Hz, 1H), 5.31 (s,
2H), 3.93 (s, 6H). A solution of N-[3-benzyloxy-2-(triﬂuoromethyl)
phenyl]-6,7-dimethoxy-quinazolin-4-amine (27 mg, 0.06 mmol) in
TFA (0.5 mL, 6.53 mmol) was heated for 45 min at 75 C in the
microwave. The yellow solution produced was concentrated under
reduced pressure and puriﬁed by preparative HPLC to afford 17
(9 mg, 42%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) d 10.53
(br s, 1H), 9.47 (s, 1H), 8.25 (s, 1H), 7.78 (s, 1H), 7.45 (t, J ¼ 8.15 Hz,
1H), 7.16 (s, 1H), 6.99 (d, J ¼ 8.19 Hz, 1H), 6.85 (d, J ¼ 7.91 Hz, 1H),
3.92 (s, 3H), 3.92 (s, 3H).
5 .1.1.10 . 2 - ( (6 ,7 -D imethoxyqu inazo l in -4-y l )amino) -6-
hydroxybenzonitrile (18). A mixture of 3 (126 mg, 0.56 mmol), 46e
(75 mg, 0.56 mmol) and 5e6N HCl in IPA (0.01 mL) in IPA returned
the crude product. The crude material was dissolved in 7N
ammonia inmethanol, preabsorbed onto silica and puriﬁed by ﬂash
column chromatography eluting with 0e100% ethyl acetate inisohexane then 0e10% methanol in ethyl acetate to return 18
(11 mg, 6%) as a pale yellow solid. 1H NMR (300 MHz, DMSO-d6)
d 13.07 (d, J¼ 6.22 Hz,1H), 9.47 (s, 1H), 9.08 (d, J¼ 5.93 Hz,1H), 7.99
(s, 1H), 7.37e7.44 (m, 2H), 7.12 (d, J ¼ 8.01 Hz, 1H), 6.51 (d,
J ¼ 8.67 Hz, 1H), 4.02 (s, 3H), 3.98 (s, 3H).
5.1.1.11. 5-((6,7-Dimethoxyquinazolin-4-yl)amino)-2-ﬂuorophenol
hydrochloride (19). A mixture of 3 (75 mg, 0.33 mmol) and 5-
amino-2-ﬂuorophenol (42 mg, 0.33 mmol) in MeCN afforded 19
(75 mg, 64%) as an off-white solid. 1H NMR (300 MHz, DMSO-d6)
d 11.27 (s, 1H), 10.24 (br s, 1H), 8.81 (s, 1H), 8.27 (s, 1H), 7.35 (s, 1H),
7.32 (dd, J ¼ 2.54, 8.01 Hz, 1H), 7.24 (dd, J ¼ 8.76, 11.02 Hz, 1H),
7.05e7.11 (m, 1H), 4.01 (s, 3H), 3.99 (s, 3H).
5 .1.1.12 . 5 - ( (6 ,7 -D imethoxyqu inazo l in -4-y l )amino) -2 -
methoxyphenol hydrochloride (22). A mixture of 3 (100 mg,
0.45 mmol) and 5-amino-2-methoxyphenol (62 mg, 0.45 mmol) in
MeCN afforded 22 (141 mg, 87%) as a yellow solid. 1H NMR
(300MHz, DMSO-d6) d 11.07 (s, 1H), 9.32 (br s, 1H), 8.78 (s, 1H), 8.18
(s, 1H), 7.30 (s, 1H), 7.10 (s, 1H), 6.98e7.07 (m, 2H), 4.00 (s, 6H), 3.82
(s, 3H).
5.1.1.13. 3-((6,7-Dimethoxyquinazolin-4-yl)amino)-5-ﬂuorophenol
hydrochloride (23). A mixture of 3 (75 mg, 0.33 mmol) and 46f
(68 mg, 0.40 mmol) in MeCN afforded 23 (18 mg, 15%) as a beige
solid. 1H NMR (300 MHz, DMSO-d6) d 11.14 (br s, 1H), 10.25 (br s,
1H), 8.88 (s, 1H), 8.25 (s, 1H), 7.34 (s, 1H), 7.12 (td, J ¼ 1.85, 10.62 Hz,
1H), 7.01e7.06 (m, 1H), 6.54 (td, J ¼ 2.11, 10.76 Hz, 1H), 4.02 (s, 3H),
4.00 (s, 3H).
5.1.1.14. 3-((6,7-Dimethoxyquinazolin-4-yl)amino)-5-methylphenol
hydrochloride (24). A mixture of 3 (75 mg, 0.33 mmol) and 3-
amino-5-methylphenol (41 mg, 0.33 mmol) in MeCN afforded 24
(76 mg, 66%) as a green solid. 1H NMR (300 MHz, DMSO-d6) d 11.19
(s, 1H), 9.65 (br s, 1H), 8.81 (s, 1H), 8.28 (s, 1H), 7.38 (s, 1H), 6.95 (s,
1H), 6.90 (s, 1H), 6.57 (s, 1H), 4.01 (s, 3H), 3.99 (s, 3H), 2.27 (s, 3H).
5.1.1.15. 4-Chloro-3-((6,7-dimethoxyquinazolin-4-yl)amino)phenol
(26). A mixture of 3 (75 mg, 0.33 mmol) and 3-amino-4-
chlorophenol (48 mg, 0.33 mmol) in MeCN returned the crude
product which was puriﬁed by preparative HPLC (high pH) to afford
26 (8 mg, 6%) as a white solid. 1H NMR (300 MHz, DMSO-d6) d 9.82
(br s, 1H), 9.39 (s, 1H), 8.33 (s, 1H), 7.81 (s, 1H), 7.33 (d, J ¼ 8.67 Hz,
1H), 7.18 (s, 1H), 6.96 (d, J ¼ 2.83 Hz, 1H), 6.73 (dd, J ¼ 2.83, 8.67 Hz,
1H), 3.93 (s, 6H).
5.1.1.16. 3-((6,7-Dimethoxyquinazolin-4-yl)amino)-4-methylphenol
hydrochloride (27). A mixture of 3 (100 mg, 0.45 mmol) and 2-
amino-4-hydroxytoluene (60 mg, 0.49 mmol) in MeCN afforded
27 (81mg, 48%) as a pale brown solid. 1H NMR (300MHz, DMSO-d6)
d 11.30 (s, 1H), 9.57 (br s, 1H), 8.72 (s, 1H), 8.27 (s, 1H), 7.36 (s, 1H),
7.16 (d, J¼ 8.52 Hz,1H), 6.72e6.78 (m, 2H), 4.00 (s, 6H), 2.07 (s, 3H).
5.1.1.17. 2,4-Dichloro-5-((6,7-dimethoxyquinazolin-4-yl)amino)
phenol hydrochloride (29). A mixture of 3 (100 mg, 0.45 mmol) and
5-amino-2,4-dichlorophenol (79mg, 0.45mmol) in MeCN returned
the crude product which was recrystallized from MeCN/MeOH to
afford 29 (31 mg, 36%) as a white solid. 1H NMR (300 MHz, DMSO-
d6) d 11.36 (br s, 1H), 10.96 (s, 1H), 8.79 (s, 1H), 8.16 (s, 1H), 7.71 (s,
1H), 7.32 (s, 1H), 7.16 (s, 1H), 4.01 (s, 3H), 4.00 (s, 3H).
5.1.1.18. 4-Chloro-5-((6,7-dimethoxyquinazolin-4-yl)amino)-2-
methylphenol hydrochloride (31). A mixture of 3 (142 mg,
0.63 mmol) and 5-amino-4-chloro-2-methyl-phenol (100 mg,
0.63 mmol) in MeCN returned the crude product which was
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white solid. 1H NMR (300 MHz, DMSO-d6) d 11.17 (br s, 1H), 9.99 (br
s, 1H), 8.76 (s, 1H), 8.11 (br s, 1H), 7.25e7.36 (m, 2H), 6.91 (s, 1H),
4.01 (s, 3H), 3.99 (s, 3H), 2.18 (s, 3H).
5.1.1.19 . 3-((6 ,7-Dimethoxyquinazol in-4-yl )amino)-2 ,6-
diﬂuorophenol hydrochloride (32). A mixture of 3 (36 mg,
0.16 mmol) and 46b (23 mg, 0.16 mmol) in MeCN afforded 32
(30 mg, 51%) as an off-white. 1H NMR (300 MHz, DMSO-d6) d 11.30
(br s, 1H), 10.53 (br s, 1H), 8.80 (s, 1H), 8.19 (s, 1H), 7.33 (s, 1H),
7.14e7.22 (m, 1H), 6.93e7.02 (m, J ¼ 5.51, 7.96 Hz, 1H), 4.01 (s, 4H),
4.00 (s, 3H).
5.1.1.20 . 3-((6 ,7-Dimethoxyquinazol in-4-yl)amino)-2 ,4-
diﬂuorophenol (33). Amixture of 3 (50mg, 0.22mmol), 46c (39mg,
0.27 mmol) and 4 N HCl in dioxane (0.2 mL, 0.80 mmol) in 1,4-
dioxane was heated in the microwave at 100 C for 30 min. The
reaction mixture was cooled and evaporated to dryness. The res-
iduewas partitioned between DCM and sat. NaHCO3, separated and
evaporated to dryness. The residue was puriﬁed by preparative
HPLC to afford 33 (17 mg, 22%) as a white solid. 1H NMR (300 MHz,
DMSO-d6) d 9.93 (br s, 1H), 9.43 (s, 1H), 8.34 (s, 1H), 7.84 (s, 1H), 7.21
(s, 1H), 6.87e7.06 (m, 2H), 3.94 (s, 6H). HRMS (ESI) m/z [M þ H]þ
calcd for C16H13F2N3O3: 334.1003. Found: 334.1004.
5.1.1.21. 4-Chloro-3-((6,7-dimethoxyquinazolin-4-yl)amino)-2-
ﬂuorophenol (34). A mixture of 3 (50 mg, 0.22 mmol), 46d (43 mg,
0.27 mmol) and 4 N HCl in dioxane (0.2 mL, 0.80 mmol) in 1,4-
dioxane was heated in the microwave at 100 C for 30 min. The
reaction was cooled and evaporated to dryness. The residue was
partitioned between DCM and sat. NaHCO3, separated and evapo-
rated to dryness. The residue was puriﬁed by preparative HPLC to
afford 34 (7 mg, 9%) as a white solid. 1H NMR (300 MHz, DMSO-d6)
d 10.26 (br s, 1H), 9.47 (s, 1H), 8.31 (s, 1H), 7.86 (s, 1H), 7.23 (dd,
J ¼ 1.88, 8.95 Hz, 1H), 7.20 (s, 1H), 6.97 (t, J ¼ 8.85 Hz, 1H), 3.94 (s,
6H). HRMS (ESI) m/z [M þ H]þ calcd for C16H13ClFN3O3: 350.0708.
Found: 350.0708.
5.1.1.22. 3-((6,7-Dimethoxyquinazolin-4-yl)amino)-5-ﬂuoro-2-
methylphenol hydrochloride (35). A mixture of 3 (60 mg,
0.27 mmol), 46i (40 mg, 0.28 mmol) and HCl in IPA (0.01 mL) in IPA
afforded 35 (56 mg, 57%) as a white solid. 1H NMR (300 MHz,
DMSO-d6) d 11.33 (br s, 1H), 10.26 (s, 1H), 8.74 (s, 1H), 8.24 (s, 1H),
7.34 (s, 1H), 6.67e6.75 (m, 2H), 4.00 (s, 3H), 4.00 (s, 3H), 1.95 (s, 3H).
5.1.1.23. 3-((6,7-Dimethoxyquinazolin-4-yl)amino)-4-ﬂuoro-2-
methylphenol hydrochloride (36). A mixture of 3 (80 mg,
0.35 mmol) and 3-amino-4-ﬂuoro-2-methyl-phenol [20] (100 mg,
0.71 mmol) in MeCN afforded 36 (42 mg, 15%) as an off-white solid.
1H NMR (300 MHz, DMSO-d6) d 11.12 (br s, 1H), 9.69 (s, 1H), 8.75 (s,
1H), 8.23 (s, 1H), 7.32 (s, 1H), 7.04 (t, J ¼ 9.07 Hz, 1H), 6.88 (dd,
J¼ 4.62, 8.95 Hz, 1H), 4.01 (s, 3H), 4.00 (s, 3H), 2.03 (s, 3H). 13C NMR
(75 MHz, DMSO-d6): d 159.4, 156.4, 152.5, 151.9 (2), 149.4, 148.9,
135.4, 123.7 (2), 123.5, 114.2, 114.1, 112.7, 112.4, 106.5, 103.8, 99.7,
56.8, 56.4. HRMS (ESI) m/z [M þ H]þ calcd for C17H16FN3O3:
330.1254. Found: 330.1254.
5.1.1.24. 4-Chloro-3-((6,7-dimethoxyquinazolin-4-yl)amino)-2-
methylphenol (37). A mixture of 3 (50 mg, 0.22 mmol), 3-amino-4-
chloro-2-methyl-phenol [21] (42 mg, 0.27 mmol) and 4N HCl in
dioxane (0.2 mL, 0.8 mmol) in 1,4-dioxane was heated in the mi-
crowave at 100 C for 30 min. The reaction was cooled and evap-
orated to dryness. The residue was partitioned between DCM and
sat. NaHCO3, separated and evaporated to dryness. The residue was
puriﬁed by preparative HPLC (high pH) to afford 37 (15 mg, 20%) asa white solid. 1H NMR (300 MHz, DMSO-d6) d 9.73 (s, 1H), 9.37 (s,
1H), 8.24 (s, 1H), 7.86 (s, 1H), 7.21 (d, J ¼ 8.51 Hz, 1H), 7.17 (s, 1H),
6.84 (d, J ¼ 8.67 Hz, 1H), 3.93 (s, 6H), 1.99 (s, 3H).
5.1.1.25. 2-Chloro-3-((6,7-dimethoxyquinazolin-4-yl)amino)-6-
methylphenol hydrochloride (38). A mixture of 3 (500 mg,
2.23 mmol) and 3-amino-2-chloro-6-methylphenol (351 mg,
2.23 mmol) in IPA afforded 38 (713 mg, 84%) as a beige solid. 1H
NMR (300 MHz, DMSO-d6) d 11.52 (br s, 1H), 9.45 (s, 1H), 8.75 (s,
1H), 8.27 (s, 1H), 7.40 (s, 1H), 7.19 (d, J ¼ 8.10 Hz, 1H), 6.93 (d,
J ¼ 8.01 Hz, 1H), 4.00 (s, 6H), 2.28 (s, 3H).
5.1.1.26. 2,4-Dichloro-3-((6,7-dimethoxyquinazolin-4-yl)amino)
phenol (39). A mixture of 3 (100 mg, 0.45 mmol), 46g (158 mg,
0.90 mmol) and 4N HCl in dioxane (0.2 mL, 0.80 mmol) in 1,4-
dioxane was heated in the microwave at 140 C for 5 h. The reac-
tion was cooled and evaporated to dryness. The residue was par-
titioned between DCM/IPA and sat. NaHCO3, separated and
evaporated to dryness. The residue was puriﬁed by ﬂash chroma-
tography eluting with an isohexane/ethyl acetate gradient to afford
39 (8 mg, 5%) as a pale yellow solid. 1H NMR (300 MHz, DMSO-d6)
d 10.56 (s, 1H), 9.58 (s, 1H), 8.27 (s, 1H), 7.86 (s, 1H), 7.38 (d,
J ¼ 8.85 Hz, 1H), 7.19 (s, 1H), 7.01 (d, J ¼ 8.85 Hz, 1H), 3.94 (s, 6H).
5.1.1.27. 2-Chloro-3-((6,7-dimethoxyquinazolin-4-yl)amino)-4-
ﬂuorophenol (40). A mixture of 3 (100 mg, 0.45 mmol), 3-amino-2-
chloro-4-ﬂuoro-phenol [20] (108 mg, 0.67 mmol) and 4N HCl in
dioxane (0.4 mL, 1.6 mmol) in 1,4-dioxane was heated in the mi-
crowave at 100 C for 90 min. The reactionwas cooled, diluted with
DCM and washed with sat. NaHCO3, separated and evaporated to
dryness. The residue was puriﬁed by preparative HPLC to afford 40
(26 mg, 17%) as a white solid. 1H NMR (300 MHz, DMSO-d6) d 10.22
(s, 1H), 9.46 (s, 1H), 8.29 (s, 1H), 7.86 (s, 1H), 7.13e7.22 (m, 2H), 6.96
(dd, J ¼ 4.85, 9.09 Hz, 1H), 3.94 (s, 6H). 13C NMR (75 MHz, DMSO-
d6): d 157.4, 154.3, 153.1, 150.3, 147.8, 146.8, 125.5, 125.3, 119.9, 114.1,
113.8, 108.3, 107.0, 101.8, 56.0, 55.8. HRMS (ESI) m/z [M þ H]þ calcd
for C16H13ClFN3O3: 350.0708. Found: 350.0708.
5.1.1.28. 3-((6,7-Dimethoxyquinazolin-4-yl)(methyl)amino)phenol
hydrochloride (41). A mixture of 3 (84 mg, 0.37 mmol) and 53
(140 mg, 0.97 mmol) in MeCN afforded 41 (88 mg, 68%) as a light
brown solid. 1H NMR (300MHz, DMSO-d6) d 10.17 (br s, 1H), 8.97 (s,
1H), 7.36e7.43 (m, 2H), 6.90e6.99 (m, 3H), 6.34 (s, 1H), 3.92 (s, 3H),
3.70 (s, 3H), 3.26 (s, 3H).
5.1.1.29. 3-((6,7-Dimethoxyquinazolin-4-yl)oxy)phenol (42). A
mixture of 3 (200 mg, 0.89 mmol), resorcinol (118 mg, 1.07 mmol)
and potassium carbonate (390 mg, 2.82 mmol) in MeCN (10 mL)
was heated at 120 C in the microwave for 30 min. The reaction
mixture was concentrated to dryness, suspended in water then
extracted with DCM. The organic phase was concentrated to dry-
ness then puriﬁed by preparative HPLC to afford 42 (52 mg, 20%) as
awhite solid. 1H NMR (300MHz, DMSO-d6) d 9.80 (br s, 1H), 8.56 (s,
1H), 7.53 (s, 1H), 7.38 (s, 1H), 7.26 (t, J ¼ 8.05 Hz, 1H), 6.65e6.74 (m,
3H), 3.99 (s, 3H), 3.97 (s, 3H).
5.1.1.30. 3-((6,7-Dimethoxyquinazolin-4-yl)thio)phenol hydrochlo-
ride (43). A mixture of 3 (100 mg, 0.45 mmol) and 3-
mercaptophenol (0.05 mL, 0.45 mmol) in MeCN returned the
crude product whichwas recrystallized fromMeCN/MeOH to afford
43 (53 mg, 34%) as a white solid. 1H NMR (300 MHz, DMSO-d6)
d 9.72 (br. s, 1H), 8.74 (s, 1H), 7.28e7.38 (m, 3H), 7.01e7.07 (m, 2H),
6.92 (d, J ¼ 8.14 Hz, 1H), 3.99 (s, 3H), 3.99 (s, 3H).
R. Newton et al. / European Journal of Medicinal Chemistry 112 (2016) 20e32305.1.1.31. 1-(6,7-Dimethoxyquinazolin-4-yl)indolin-4-ol hydrochloride
(44). Amixture of 3 (250 mg, 1.11 mmol) and indolin-4-ol (150 mg,
1.11 mmol) in MeCN afforded 44 (350 mg, 88%) as a yellow solid. 1H
NMR (300 MHz, DMSO-d6) d 9.82 (br s,1H), 8.86 (s, 1H), 7.57 (s, 1H),
7.40 (s, 1H), 7.32 (d, J ¼ 8.10 Hz, 1H), 7.11 (t, J ¼ 8.10 Hz, 1H), 6.66 (d,
J ¼ 7.63 Hz, 1H), 4.71 (t, J ¼ 7.54 Hz, 2H), 4.01 (s, 3H), 3.91 (s, 3H),
3.11 (t, J ¼ 7.54 Hz, 2H).
5 .1.1. 3 2 . 1 - ( 6 , 7 -D ime t h o x y qu i n a z o l i n - 4 - y l ) - 1, 2 , 3 , 4 -
tetrahydroquinolin-5-ol hydrochloride (45). A mixture of 3 (250 mg,
1.11 mmol), 1,2,3,4-tetrahydro-quinolin-5-ol hydrochloride
(206 mg, 1.11 mmol) in MeCN (12 mL) afforded 45 (390 mg, 94%) as
an orange solid. 1H NMR (300 MHz, DMSO-d6) d 9.81 (br s, 1H), 8.93
(s, 1H), 7.31 (s, 1H), 6.88 (d, J ¼ 8.10 Hz, 1H), 6.62e6.75 (m, 2H),
6.20e6.42 (m,1H), 4.12 (d, J¼ 5.46 Hz, 2H), 3.96 (s, 3H), 3.43 (s, 3H),
2.79 (t, J ¼ 6.64 Hz, 2H), 1.98e2.16 (m, 2H).
5.1.2. Procedures for synthesis of anilines 46aei, 49h, 49i, 51 and
53
5.1.2.1. 3-Amino-2-ethylphenol (46a). To an ice-cooled solution of
2-ethyl-3-methoxyaniline [22] (141 mg, 0.93 mmol) in DCM (1 mL)
was added BBr3 (1 M solution in DCM, 4.66 mL, 4.66 mmol) drop-
wise under nitrogen. The reaction mixture was stirred at room
temperature overnight then poured into ice water, neutralized with
sodium carbonate and separated. The aqueous phase was further
extracted with DCM (2  20 mL) and the combined organics were
dried over MgSO4, ﬁltered and concentrated under reduced pres-
sure to return 46a (128 mg, 100%) as a brown solid which was used
without further puriﬁcation. 1H NMR (300 MHz, DMSO-d6) d 8.75
(s, 1H), 6.64 (t, J ¼ 7.9 Hz, 1H), 5.97e6.19 (m, 2H), 4.96 (br. s, 2H),
2.44 (q, J ¼ 7.6 Hz, 2H), 0.98 (t, J ¼ 7.6 Hz, 3H).
5.1.2.2. 3-Amino-2,6-diﬂuorophenol (46b). A mixture of 2,4-
diﬂuoro-3-methoxyaniline (500 mg, 3.14 mmol) and pyridinium
chloride (1.0 g, 8.89 mmol) was heated at 200 C for 1 h then
allowed to cool to room temperature. The reaction mixture was
diluted with water (50 mL) and extracted with DCM (50 mL). The
organic phase was concentrated under reduced pressure under
reduced pressure to return the crude product which was puriﬁed
by ﬂash column chromatography, eluting with 0e100% EtOAc in
isohexane, then 1% 7N ammonia in methanol/EtOAc to return 46b
(23 mg, 5%). 1H NMR (300 MHz, DMSO-d6) d 9.65 (s, 1H), 6.67 (ddd,
J ¼ 2.17, 8.90, 10.78 Hz, 1H), 6.15 (dt, J ¼ 5.09, 9.18 Hz, 1H), 4.83 (s,
2H).
5.1.2.3. 3-Amino-2,4-diﬂuorophenol (46c). A mixture of 2,6-
diﬂuoro-3-methoxyaniline (1.0 g, 6.28 mmol) and pyridinium
chloride (2.1 g, 17.79 mmol) was heated at 200 C for 1 h then
allowed to cool to room temperature. The reaction mixture was
diluted with water (25 mL) and then neutralized with Na2HCO3.
The resultant precipitate was isolated by ﬁltration, washed with
water and dried overnight at 40 C under vacuum to return 46c
(470mg, 52%) as a red solid. 1H NMR (300 MHz, DMSO-d6) d 9.32 (s,
1H), 6.64 (ddd, J¼ 2.17, 8.92,10.86 Hz,1H), 6.07 (dt, J¼ 5.04, 9.16 Hz,
1H), 5.03 (s, 2H).
5.1.2.4. 3-Amino-4-chloro-2-ﬂuorophenol (46d). A mixture of 6-
chloro-2-ﬂuoro-3-methoxyaniline (1.0 g, 5.7 mmol) and pyr-
idinium chloride (1.97 g, 17.1 mmol) was heated at 200 C for 1 h
then allowed to cool to room temperature. The reaction mixture
was diluted with water (25 mL) and then neutralized with sodium
bicarbonate. The resultant precipitate was isolated by ﬁltration,
washed with water and dried overnight at 40 C under vacuum to
return 46d (244 mg, 27%). 1H NMR (300 MHz, DMSO-d6) d 9.64 (s,
1H), 6.82 (dd, J ¼ 2.07, 8.85 Hz, 1H), 6.17 (t, J ¼ 8.81 Hz, 1H), 5.17 (s,2H).
5.1.2.5. 2-Amino-6-hydroxybenzonitrile (46e). A solution of 2-
hydroxy-6-nitrobenzonitrile [23] (1.3 g, 7.92 mmol) in ethanol
(100 mL) was treated with 5% Pd/C (450 mg). The ﬂask was evac-
uated and ﬁlled with nitrogen three times, then evacuated and
ﬁlled with hydrogen three times. The reaction mixture was stirred
under an atmosphere of hydrogen at room temperature overnight,
then ﬂushed with nitrogen and ﬁltered through Celite. The ﬁltrate
was concentrated under reduced pressure to return 46e (910 mg,
77%). 1H NMR (300 MHz, DMSO-d6) d 10.39 (br. s., 1H), 7.03 (t,
J ¼ 8.19 Hz, 1H), 6.17 (d, J ¼ 8.23 Hz, 1H), 6.06 (d, J ¼ 8.20 Hz, 1H),
5.79 (s, 2H).
5.1.2.6. 3-Amino-5-ﬂuorophenol (46f). To a solution of 3-ﬂuoro-5-
nitrophenol (1.0 g, 6.37 mmol) in ethanol (20 mL) and acetic acid
(20 mL) was added iron powder (0.36 g, 6.37 mmol) and the
mixture heated at reﬂux under nitrogen for 2 h then cooled to room
temperature and ﬁltered through Celite. The ﬁltrate was concen-
trated under reduced pressure to return the crude product which
was puriﬁed by ﬂash column chromatography, eluting with 0e20%
MeOH in DCM to return 46f (820 mg, 86%) as a brown oil which
solidiﬁed on standing. 1H NMR (300 MHz, DMSO-d6) d 5.82 (t,
J ¼ 1.93 Hz, 1H), 5.78 (dt, J ¼ 11.60, 2.00 Hz, 1H), 5.69 (dt, J ¼ 11.11,
2.07 Hz, 1H).
5.1.2.7. 3-Amino-2,4-dichlorophenol (46g). To a stirred solution of
2,4-dichloro-3-nitrophenol (2.0 g, 9.62 mmol) in ethanol (50 mL)
was added iron powder (2.15 g, 38.46 mmol), ammonium chloride
(2.06 g, 38.46 mmol) and water (25 mL). The reaction heated at
reﬂux for 6 h, cooled a little, then ﬁltered through Celite and
washed with hot ethanol. The ﬁltrate was concentrated under
reduced pressure to remove ethanol, then extracted with DCM
(3  25 mL), dried over MgSO4, ﬁltered and concentrated under
reduced pressure to return the crude product which was puriﬁed
by ﬂash column chromatography, eluting with 0e20% EtOAc in
isohexane to return 46g (1.45 g, 85%) as a brown solid. 1H NMR
(300 MHz, DMSO-d6) d 10.01 (s, 1H), 6.99 (d, J ¼ 8.67 Hz, 1H), 6.24
(d, J ¼ 8.76 Hz, 1H), 5.28 (br s, 2H).
5.1.2.8. 3-Amino-2-methoxyphenol (46h). To a solution of 49h
(358 mg, 1.44 mmol) in THF (10 mL) was added water (5 mL) and
sodium perborate (569 mg, 3.7 mmol). The mixture was stirred at
ambient temperature overnight. Excess THF was removed under
reduced pressure. The residue was stirred with sat. NH4Cl solution
(10mL) and DCM (50mL) for 1 h, then separated. The organics were
concentrated under reduced pressure and puriﬁed by ﬂash column
chromatography, eluting with 0e60% EtOAc in isohexane, to return
46h (120 mg, 57%) as an off-white solid. 1H NMR (300 MHz, DMSO-
d6) d 8.80 (s, 1H), 6.55 (t, J ¼ 7.84 Hz, 1H), 6.12 (d, J ¼ 7.95 Hz, 1H),
6.05 (d, J ¼ 7.77 Hz, 1H), 4.71 (s, 2H), 3.62 (s, 3H).
5.1.2.9. 3-Amino-5-ﬂuoro-2-methylphenol (46i). To a solution of 49i
(761 mg, 1.8 mmol) in THF (40 mL) was added water (20 mL) and
sodium perborate (961 mg, 6.2 mmol). The mixture was stirred at
ambient temperature overnight. THF was removed under reduced
pressure and the aqueous extracted with DCM (50 mL). The or-
ganics were concentrated under reduced pressure and puriﬁed by
ﬂash column chromatography, eluting with 0e30% EtOAc in iso-
hexane, to return 46i (225 mg, 85%) as a light brown solid. 1H NMR
(300 MHz, DMSO-d6) d 9.20 (s, 1H), 5.79e5.93 (m, 2H), 4.99 (s, 2H),
1.81 (s, 3H).
5.1.2.10. 2-Methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
aniline (49h). A suspension of 3-bromo-2-methoxyaniline
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and potassium acetate (729 mg, 7.42 mmol) in 1,4-dioxane (8 mL)
was sparged with nitrogen for 5 min. Pd(dppf)Cl2$DCM (173 mg,
0.21mmol) was added and themixturewas heated under reﬂux for
2.5 h then cooled to room temperature. The reaction was diluted
with DCM (35 mL) and washed with water (35 mL). The organic
phase was concentrated under reduced pressure then puriﬁed by
ﬂash column chromatography, eluting with 0e100% EtOAc in iso-
hexane, to return 49h (358 mg, 58%) an off-white solid. 1H NMR
(300 MHz, DMSO-d6) d 6.72e6.83 (m, 3H), 4.80 (s, 2H), 3.64 (s, 3H),
1.28 (s, 12H).
5.1.2 .11. 5-Fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)aniline (49i). A suspension of 3-bromo-5-ﬂuoro-
2-methyl-aniline [24] (725 mg, 3.55 mmol), bis(pinacolato)diboron
(1.1 g, 4.26 mmol) and potassium acetate (1.0 g, 10.66 mmol) in 1,4-
dioxane (35 mL) was sparged with nitrogen for 5 min. Pd(dppf)
Cl2$DCM (174 mg, 0.21 mmol) was added and the mixture was
heated under reﬂux for 4 h. The reaction was cooled to room
temperature and concentrated under reduced pressure. The residue
was diluted with EtOAc, ﬁltered through Celite, then concentrated
under reduced pressure to return the crude product which was
puriﬁed by ﬂash column chromatography, eluting with 0e50%
EtOAc in isohexane, to return 49i (761 mg, 78%). 1H NMR (300MHz,
CDCl3) d 6.90 (dd, J ¼ 2.68, 9.18 Hz, 1H), 6.49 (dd, J ¼ 2.64, 10.17 Hz,
1H), 2.33 (s, 3H), 1.36 (s, 12H).
5.1.2.12. 1-Benzyloxy-3-bromo-2-(triﬂuoromethyl)benzene (50).
To an ice-cooled solution of benzyl alcohol (2.19 mL, 21.2 mmol) in
DMF (30 mL) was added sodium hydride (0.97 g 60% dispersion on
mineral oil, 24.23 mmol) portionwise. The mixture was stirred for
1 h before adding 3-ﬂuoro-2-(triﬂuoromethyl)bromobenzene
(4.91 g, 20.19 mmol) portionwise. The mixture was stirred at
ambient temperature overnight, then diluted with EtOAc (50 mL)
andwashedwithwater (3 50mL) and brine (50mL). The organics
were concentrated under reduced pressure then puriﬁed by ﬂash
column chromatography, eluting with 0e30% EtOAc in isohexane,
to return 50 (5.6 g, 84%) as a colourless oil. 1H NMR (300 MHz,
CDCl3) d 6.85e7.77 (m, 8H), 4.92e5.25 (m, 2H).
5.1.2.13. 3-(Benzyloxy)-2-(triﬂuoromethyl)aniline (51). A mixture of
50 (5.6 g, 16.79 mmol), benzophenone imine (3.1 mL, 18.47 mmol),
cesium carbonate (4.88 g, 25.19 mmol), Pd(OAc)2 (188 mg,
0.8400 mmol) and BINAP (1.05 g, 1.68 mmol) in toluene (65 mL)
was ﬂushed with nitrogen and heated under reﬂux overnight. The
reaction mixture was cooled and ﬁltered, then the ﬁltrate was
dilutedwith EtOAc (50mL) andwashed successivelywith 0.5MHCl
(2  25 mL), sat. NaHCO3 (2  25 mL) and brine (25 mL). The or-
ganics were dried over MgSO4, ﬁltered and concentrated under
reduced pressure to give the crude product which was puriﬁed by
ﬂash column chromatography, eluting with 0e30% EtOAc in iso-
hexane, to return N-[3-benzyloxy-2-(triﬂuoromethyl)phenyl]-1,1-
diphenyl-methanimine (4.7 g, 64%) as an orange solid. Analysis
indicated the product contained some aromatic impurities and was
progressed without additional puriﬁcation. 1H NMR (300 MHz,
CDCl3) d 7.77 (br d, J ¼ 7.44 Hz, 2H), 7.05e7.56 (m, 14H), 6.59 (d,
J¼ 8.38 Hz,1H), 6.19 (d, J¼ 8.01 Hz,1H), 5.10 (s, 2H). To a solution of
crude N-[3-benzyloxy-2-(triﬂuoromethyl)phenyl]-1,1-diphenyl-
methanimine (600 mg, 1.39 mmol) in THF (15 mL) was added 2 M
HCl (3 mL). The reaction mixture was stirred overnight at ambient
temperature then diluted with EtOAc (50 mL) and washed with sat.
NaHCO3 (2  25 mL). The organics were concentrated under
reduced pressure, then puriﬁed by ﬂash column chromatography,
eluting with 0e25% EtOAc in isohexane, to return 51 (286 mg, 77%)
as a yellow oil. 1H NMR (300 MHz, DMSO-d6) d 7.28e7.47 (m, 5H),7.13 (t, J ¼ 8.24 Hz, 1H), 6.40 (d, J ¼ 8.48 Hz, 1H), 6.35 (d, J ¼ 8.10 Hz,
1H), 5.59 (s, 2H), 5.11 (s, 2H).
5.1.2.14. 3-(Methylamino)phenol (53). To a solution of 52 [25]
(1.07 g, 5.11 mmol) in THF (20 mL) was added LiAlH4 (1.3 g,
30.96 mmol) portionwise. The mixture was heated under reﬂux for
4 h, then cooled to ambient temperature. Sat. Na2SO4 (30 mL) was
cautiously added and the reactionmixture stirred vigorously for 1 h
before being acidiﬁed with 2 M HCl. The reaction mixture was
extracted with EtOAc (50 mL), thenwashed with brine (25 mL) and
dried over MgSO4, ﬁltered and concentrated under reduced pres-
sure to return 53 (140 mg, 22%). 1H NMR (300 MHz, DMSO-d6)
d 8.88 (br s, 1H), 6.73e6.88 (m, 1H), 5.90e6.01 (m, 3H), 5.45 (br s,
1H), 2.60 (s, 3H).
5.2. Biological evaluation
5.2.1. Biochemical assay
Kinase activity was detected using CisBio HTRF kinEASE kit
based on time-resolved ﬂuorescence transfer (FRET). The assay was
performed in 384-well white plates (Corning #3574) in a reaction
volume of 10 mL containing 1 CisBio enzymatic buffer supple-
mentedwith a ﬁnal concentration of 5mMMgCl2,1 mMDTT,10 nM
SEB and 0.01% Triton X100 for RET. The same buffer was used for
the KDR biochemical assay with the addition of 2 mM MnCl2.
Inhibitors were pre-incubated in the plate for 15 min with 5 mL
kinase and assay buffer at the following concentrations; 13 pM RET
(Carna Biosciences; 08-159) and 150 pM KDR (Millipore; 14-630).
The reactionwas initiated by the addition of 5 mL ATP and substrate
at 2 ﬁnal reaction concentrations. For RET, this was 18 mM and
2 mM; for KDR, this was 16 mM and 1 mM, respectively. Reactions
were performed at ATP Km for each target. The assay was allowed to
proceed at room temperature for 20 min before terminating with
the addition of 10 mL HTRF detection buffer containing EDTA sup-
plemented with TK-antibody labelled with Eu3þ-Cryptate (1:100
dilution) and streptavidin-XL665 (128 nM). Following incubation at
room temperature for 1 h, FRET signal was measured using the
Pherastar FS Microplate Reader.
5.2.2. BaF3 cellular assay
The system originally developed by Daley and Baltimore [26]
was used, whereby IL3-dependent BaF3 cells are modiﬁed to ex-
press an activated recombinant kinase. Following removal of IL3,
the modiﬁed cells are dependent on the activity of the recombinant
kinase for survival and proliferation. The BaF3 cell lines, expressing
KIF5B-RET (gift from Pasi Janne [27]) and KDR (Advanced Cellular
Dynamics, San Diego) were maintained in RPMI-1640 media con-
taining 10% FBS and appropriate antibiotics. Non-modiﬁed BaF3
cells (WT) were maintained in RPMI-1640 media containing 10%
FBS and supplemented with 10 ng/mL recombinant mouse IL3
(R&D systems). For assessment of compound IC50, cells were plated
into 384-well plates at 1500 or 3000 cells per well in 30 mL culture
medium and compounds dispensed using an acoustic liquid
handling platform (LABCYTE). Following incubation of the cells for
48 h at 37 C in a humidiﬁed 5% CO2 atmosphere, viability was
determined by addition of 10 mL CellTiter-Glo reagent (Promega)
and measurement of luminescence.
5.2.3. Pharmacokinetics
All studies were conducted after review by the Animal Welfare
and Ethical Review Body at CRUK:MI and in accordance with the
University of Manchester Policy on the use of animals in research.
All work was carried out in compliance with the Animals (Scientiﬁc
Procedures) Act 1986. Pharmacokinetics were studied in male CD-1
mice following single intravenous or oral administration. Blood
R. Newton et al. / European Journal of Medicinal Chemistry 112 (2016) 20e3232samples were collected as dried blood spots and assayed following
solvent extraction through a phospholipid removal plate followed
by LC-MS/MS analysis. The resulting concentration-time data were
analysed by non-compartmentalmethods (PK Solver, Excel Add-In).
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